Analysis of subgroup with clinically significant hypoglycaemia and/or symptoms of hypoglycaemia
hypoglycaemia
HYPOGLYCAEMIA
A total of 20/43 (46.5%) and 19/42 (45.2%) participants administered a double dose of icodec or glargine U100, respectively, and 20/38 (52.6%) and 29/40 (72.5%) participants administered a triple dose, respectively, experienced clinically significant hypoglycaemia (PGParticipant flow diagram showing the number of individuals included in the subgroup analysis of physiological response to hypoglycaemia following double and triple dose of either insulin icodec or insulin glargine U100. 